Related Experiment Video
Updated: Aug 13, 2026

A Preclinical Murine Model of Hepatic Metastases
Published on: September 27, 2014
Mist1-KrasG12D knock-in mice develop mixed differentiation metastatic exocrine pancreatic carcinoma and
David A Tuveson1, Liqin Zhu, Aarthi Gopinathan
1Department of Medicine, Abramson Family Cancer Research Institute, Philadelphia, Pennsylvania, USA. tuvesond@mail.med.upenn.edu
Abstract:
Despite the prevalence of oncogenic Kras mutations in the earliest stages of pancreatic ductal adenocarcinoma, the cellular compartment in which oncogenic Kras initiates tumorigenesis remains unknown. To address this, we have gene targeted KrasG12D into the open reading frame of Mist1, a basic helix-loop-helix transcription factor that is expressed during pancreatic development and required for proper pancreatic acinar organization. Although the pancreata of Mist1(KrasG12D/+) mutant mice predictably exhibited acinar metaplasia and dysplasia, the frequent death of these mice from invasive and metastatic pancreatic cancer with mixed histologic characteristics, including acinar, cystic, and ductal features, was unexpected and in contrast to previously described mutant mice that ectopically expressed the Kras oncogene in either acinar or ductal compartments. Interestingly, many of the mutant mice developed hepatocellular carcinoma, implicating Mist1(KrasG12D/+) cells in both pancreatic and hepatic neoplasia. Concomitant Trp53+/- mutation cooperated with Mist1(KrasG12D/+) to accelerate lethality and was associated with advanced histopathologic findings, including parenchymal liver metastasis. These findings suggest that Mist1-expressing cells represent a permissive compartment for transformation by oncogenic Kras in pancreatic tumorigenesis.
Insights
Mist1-expressing cells can initiate pancreatic cancer when mutated with KrasG12D. These cells also contribute to liver cancer, suggesting a broader role in neoplasia.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Oncogenic Kras mutations are common in early pancreatic ductal adenocarcinoma.
- The specific cell type where Kras initiates pancreatic cancer is currently unknown.
Purpose of the Study:
- To investigate the cellular origin of pancreatic tumorigenesis driven by oncogenic Kras.
- To determine if Mist1-expressing cells are a potential site for Kras-initiated pancreatic cancer.
Main Methods:
- Gene targeting of KrasG12D into the Mist1 gene in mice.
- Analysis of pancreatic and hepatic neoplasia development in Mist1(KrasG12D/+) mutant mice.
- Assessment of the impact of concomitant Trp53+/- mutation.
Main Results:
- Mist1(KrasG12D/+) mice developed invasive, metastatic pancreatic cancer with mixed histologic features.
- Hepatocellular carcinoma developed in many mutant mice, indicating Mist1(KrasG12D/+) cells' role in hepatic neoplasia.
- Trp53+/- mutation accelerated lethality and advanced histopathology, including liver metastasis.
Conclusions:
- Mist1-expressing cells are a permissive compartment for oncogenic Kras-driven pancreatic tumorigenesis.
- Mist1-expressing cells contribute to both pancreatic and hepatic neoplasia.
- Targeting Mist1-expressing cells may offer a therapeutic strategy for Kras-driven cancers.

